OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
March 23, 2023
TreeFrog Therapeutics is leaping ahead in cell therapies through
resources such as new technologies and investor partnerships.
March 22, 2023
The combined solutions are currently available on the market.
March 03, 2023
The new guidance provides detailed recommendations to drug developers with a target of helping to ensure that drug developers provide adequate information to assess potency at each stage of a product’s life cycle.
March 02, 2023
Decreasing vein to vein time saves lives.
March 01, 2023
There is growing pressure for robust and economically scalable viral-vector manufacturing technologies.
February 02, 2023
A slew of late-stage clinical trials is expected to push new regenerative medicines onto the market in the next few years.
Improvement in viral vector yield has become integral to new cell and gene therapy product development.
In vivo CAR-T gene therapies could overcome the challenges faced by autologous and allogeneic treatments.
November 17, 2022
CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.
October 28, 2022
The newly formed partnership between CSafe and BioLife will expand cold chain supply chain solutions for the cell and gene therapy market.